Interferon Type I

"Interferon Type I" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA).

Descriptor ID	D007370
MeSH Number(s)	D12.644.276.374.440.890 D12.776.467.374.440.890 D23.529.374.440.890
Concept/Terms	Interferon Type I Interferon Type I Type I Interferons Interferons, Type I Interferons Type I Type I Interferon Interferon, Type I

Below are MeSH descriptors whose meaning is more general than "Interferon Type I".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Peptides [D12.644]
Intercellular Signaling Peptides and Proteins [D12.644.276]
Cytokines [D12.644.276.374]
Interferons [D12.644.276.374.440]
Interferon Type I [D12.644.276.374.440.890]
Proteins [D12.776]
Intercellular Signaling Peptides and Proteins [D12.776.467]
Cytokines [D12.776.467.374]
Interferons [D12.776.467.374.440]
Interferon Type I [D12.776.467.374.440.890]
Biological Factors [D23]
Intercellular Signaling Peptides and Proteins [D23.529]
Cytokines [D23.529.374]
Interferons [D23.529.374.440]
Interferon Type I [D23.529.374.440.890]

Below are MeSH descriptors whose meaning is related to "Interferon Type I".

Below are MeSH descriptors whose meaning is more specific than "Interferon Type I".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Interferon Type I" by people in this website by year, and whether "Interferon Type I" was a major or minor topic of these publications.

Bar chart showing 103 publications over 24 distinct years, with a maximum of 13 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	2	3
2001	2	0	2
2003	0	1	1
2005	0	2	2
2006	0	1	1
2007	2	1	3
2008	1	1	2
2009	2	5	7
2010	4	2	6
2011	6	7	13
2012	4	2	6
2013	1	1	2
2014	3	3	6
2015	2	1	3
2016	3	4	7
2017	4	3	7
2018	3	5	8
2019	3	1	4
2020	3	3	6
2021	4	1	5
2022	1	0	1
2023	5	0	5
2024	1	1	2
2025	0	1	1

Below are the most recent publications written about "Interferon Type I" by people in Profiles.

Arowosegbe A, Guo Z, Vanderleeden E, Derr AG, Wang JP. Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats. J Autoimmun. 2025 Feb; 151:103358.

View in: PubMed
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdhury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024 Aug 28; 16(762):eadj9366.

View in: PubMed
Bazzone LE, Zhu J, King M, Liu G, Guo Z, MacKay CR, Kyawe PP, Qaisar N, Rojas-Quintero J, Owen CA, Brass AL, McDougall W, Baer CE, Cashman T, Trivedi CM, Gack MU, Finberg RW, Kurt-Jones EA. ADAM9 promotes type I interferon-mediated innate immunity during encephalomyocarditis virus infection. Nat Commun. 2024 May 16; 15(1):4153.

View in: PubMed
Dong M, Fitzgerald KA. STING channels its proton power. Mol Cell. 2023 10 05; 83(19):3402-3403.

View in: PubMed
Devarajan P, Vong AM, Castonguay CH, Silverstein NJ, Kugler-Umana O, Bautista BL, Kelly KA, Luban J, Swain SL. Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15. Cell Rep. 2023 10 31; 42(10):113182.

View in: PubMed
Humphries F, Shmuel-Galia L, Jiang Z, Zhou JY, Barasa L, Mondal S, Wilson R, Sultana N, Shaffer SA, Ng SL, Pesiridis GS, Thompson PR, Fitzgerald KA. Targeting STING oligomerization with small-molecule inhibitors. Proc Natl Acad Sci U S A. 2023 08 15; 120(33):e2305420120.

View in: PubMed
Hackstein CP, Spitzer J, Symeonidis K, Horvatic H, Bedke T, Steglich B, Klein S, Assmus LM, Odainic A, Szlapa J, Kessler N, Beyer M, Schmithausen R, Latz E, Flavell RA, Garbi N, Kurts C, K?mmerer BM, Trebicka J, Roers A, Huber S, Schmidt SV, Knolle PA, Abdullah Z. Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury. J Hepatol. 2023 07; 79(1):150-166.

View in: PubMed
Gao KM, Marshak-Rothstein A, Fitzgerald KA. Type-1 interferon-dependent and -independent mechanisms in cyclic GMP-AMP synthase-stimulator of interferon genes-driven auto-inflammation. Curr Opin Immunol. 2023 02; 80:102280.

View in: PubMed
Nicastro LK, de Anda J, Jain N, Grando KCM, Miller AL, Bessho S, Gallucci S, Wong GCL, T?kel ?. Assembly of ordered DNA-curli fibril complexes during Salmonella biofilm formation correlates with strengths of the type I interferon and autoimmune responses. PLoS Pathog. 2022 08; 18(8):e1010742.

View in: PubMed
Qaisar N, Arowosegbe A, Derr AG, Kucukural A, Satish B, Racicot R, Guo Z, Trombly MI, Wang JP. Type I IFN-Driven Immune Cell Dysregulation in Rat Autoimmune Diabetes. Immunohorizons. 2021 10 26; 5(10):855-869.

View in: PubMed

People

Explore

Similar Concepts

Top Journals